Everything You Need To Know About Adopting eConsent Across Large Pharma Organizations

In 2023, more sponsors than ever before will drop paper consent.

Why?

Research shows that global patient dropout rates have risen another 4% in recent years, with 35% of dropouts naming the consent process as part of their reasoning. Given that the average cost for a delayed trial is between $600,000 and $8 million per day, sponsors are learning they can’t afford to continue using paper consent.

However, seeing value takes more than just applying eConsent to your study.

In this on-demand webinar, Camila Matheny, DCT Implementation Expert, and Annie Hesslewood, Patient & Site Global Adoption Lead, discuss the benefits of adopting consent management technology and provide best practices around developing change management and training programs to help sponsors, CROs, and sites get the most out of eConsent.

Key learning objectives:

• Learn what the different types of digital consent solutions are and how they can be implemented
• How to earn stakeholder acceptance and adoption with a robust change management process
• What the most recent regulatory guidelines and updates mean for the future of DCTs and eConsent